{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T20:27:50Z","timestamp":1768595270062,"version":"3.49.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T00:00:00Z","timestamp":1662681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To assess the economic evaluation of margetuximab plus chemotherapy over trastuzumab plus chemotherapy for women with pretreated ERBB2-positive advanced breast cancer in the United States (US) and China.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Based on the SOPHIA trial, a three-state Markov model was developed to compare the cost and efficacy of margetuximab to trastuzumab for previously treated women with ERBB2-positive advanced breast cancer. The model inputs were derived from existing literature and the US life table. Primary outcomes included lifetime costs in US dollars, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (ICER). Deterministic and probabilistic sensitivity analyses were conducted to evaluate the impact of uncertainty.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The base case analyses demonstrated that margetuximab plus chemotherapy had an increasing cost of $68,132 and $20,540 over trastuzumab plus chemotherapy in the US and China, respectively, with a gain of 0.11 and 0.09 QALYs both favored margetuximab. The ICERs for two treatment strategies were $260,176 in the US and $630,777 in China, resulting in a poor cost-effectiveness at their respective threshold of willingness to play. One-way sensitivity analyses showed that the results to be most sensitive to the price of margetuximab and that of trastuzumab. And an 11 and 82% price reduction of margetuximab would make this regimen cost-effective in the US and China, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In the US and China, margetuximab plus chemotherapy is not likely to be cost-effective for women with pretreated ERBB2-positive advanced breast cancer, whereas price reduction effectively improves insufficient cost-effectiveness.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2022.942767","type":"journal-article","created":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T06:49:50Z","timestamp":1662706190000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Economic evaluation of margetuximab vs. trastuzumab for pretreated ERBB2-positive advanced breast cancer in the US and China"],"prefix":"10.3389","volume":"10","author":[{"given":"Zhiyuan","family":"Tang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuyan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyu","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bohua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/ijc.33588","article-title":"Cancer statistics for the year 2020: an overview","volume":"149","author":"Ferlay","year":"2021","journal-title":"Int J Cancer."},{"key":"B2","volume-title":"Colorectal Cancer Facts and Figures 2020-2022","year":"2020"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jncc.2020.12.001","article-title":"Cancer incidence and mortality in China, 2015","volume":"1","author":"Zhang","year":"2021","journal-title":"J Natl Cancer Cent."},{"key":"B4","volume-title":"Breast Cancer Facts and Figures 2019-2020.","year":"2019"},{"key":"B5","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1186\/1471-2407-11-364","article-title":"A Nation-wide multicenter 10-year (1999-2008) retrospective clinical epidemiological study of female breast cancer in china","volume":"11","author":"Li","year":"2011","journal-title":"BMC Cancer."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/852748","article-title":"Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Mol Biol Int."},{"key":"B7","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1093\/jnci\/djq495","article-title":"Projections of the cost of cancer care in the United States: 2010-2020","volume":"103","author":"Mariotto","year":"2011","journal-title":"JNCI J Natl Cancer Inst."},{"key":"B8","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.9778\/cmajo.20170144","article-title":"The economic burden of cancer care in Canada: a population-based cost study","volume":"6","author":"de Oliveira","year":"2018","journal-title":"C Open."},{"key":"B9","doi-asserted-by":"publisher","first-page":"E151","DOI":"10.9778\/cmajo.20130041","article-title":"Trends in use and cost of initial cancer treatment in Ontario: a population-based descriptive study","volume":"1","author":"de Oliveira","year":"2013","journal-title":"C Open."},{"key":"B10","first-page":"23","article-title":"Comparison of treatment costs for breast cancer, by tumor stage and type of service","volume":"9","author":"Blumen","year":"2016","journal-title":"Am Heal drug benefits"},{"key":"B11","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1001\/jamaoncol.2021.8049","article-title":"Cost-effectiveness analysis of pertuzumab with trastuzumab in patients with metastatic breast cancer","volume":"8","author":"Dai","year":"2022","journal-title":"JAMA Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1200\/OP.21.00172","article-title":"Current and future management of HER2-positive metastatic breast cancer","volume":"17","author":"Mart\u00ednez-S\u00e1ez","year":"2021","journal-title":"JCO Oncol Pract."},{"key":"B13","doi-asserted-by":"publisher","first-page":"17588359211066677","DOI":"10.1177\/17588359211066677","article-title":"Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines","volume":"14","author":"Simmons","year":"2022","journal-title":"Ther Adv Med Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N Engl J Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S1470-2045(14)70178-0","article-title":"Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial","volume":"15","author":"Krop","year":"2014","journal-title":"Lancet Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1001\/jamaoncol.2020.7932","article-title":"Escriv\u00e1-de-Roman\u00ed S, et al. Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer","volume":"7","author":"Rugo","year":"2021","journal-title":"JAMA Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.jval.2018.11.014","article-title":"Cost-effectiveness analysis of pertuzumab with trastuzumab and chemotherapy compared to trastuzumab and chemotherapy in the adjuvant treatment of HER2-positive breast cancer in the United States","volume":"22","author":"Garrison","year":"2019","journal-title":"Value Health."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1111\/liv.14257","article-title":"Cost-effectiveness analysis of cabozantinib as second-line therapy in advanced hepatocellular carcinoma","volume":"39","author":"Liao","year":"2019","journal-title":"Liver Int."},{"key":"B20","doi-asserted-by":"publisher","first-page":"3761","DOI":"10.1007\/s12325-020-01418-7","article-title":"Economic evaluation of cisplatin plus gemcitabine versus paclitaxel plus gemcitabine for the treatment of first-line advanced metastatic triple-negative breast cancer in China: using markov model and partitioned survival model","volume":"37","author":"Rui","year":"2020","journal-title":"Adv Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"734594","DOI":"10.3389\/fonc.2021.734594","article-title":"Economic evaluation of sacituzumab govitecan for the treatment of metastatic triple-negative breast cancer in China and the US","volume":"11","author":"Chen","year":"2021","journal-title":"Front Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2147\/BCTT.S105618","article-title":"Economic burden related to chemotherapy-related adverse events in patients with metastatic breast cancer in an integrated health care system","volume":"8","author":"Rashid","year":"2016","journal-title":"Breast Cancer Targets Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/sj.bjc.6603326","article-title":"Health state utilities for metastatic breast cancer","volume":"95","author":"Lloyd","year":"2006","journal-title":"Br J Cancer."},{"key":"B24","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s11136-016-1388-1","article-title":"Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trial","volume":"26","author":"Shiroiwa","year":"2017","journal-title":"Qual Life Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1111\/j.1524-4733.2008.00394.x","article-title":"Health state utility scores for cancer-related anemia through societal and patient valuations","volume":"11","author":"Lloyd","year":"2008","journal-title":"Value Health."},{"key":"B26","doi-asserted-by":"publisher","first-page":"504","DOI":"10.2165\/00019053-199610050-00008","article-title":"A Cost-utility analysis of second-line chemotherapy in metastatic breast cancer","volume":"10","author":"Launois","year":"1996","journal-title":"Pharmacoeconomics."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e12733","DOI":"10.1111\/ecc.12733","article-title":"Cost-effectiveness analysis of fulvestrant vs. anastrozole as first-line treatment for hormone receptor-positive advanced breast cancer","volume":"6","author":"Ding","year":"2017","journal-title":"Eur J Cancer Care."},{"key":"B28","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1634\/theoncologist.2009-0181","article-title":"Lapatinib plus capecitabine in women with HER-2\u2013positive advanced breast cancer: final survival analysis of a phase III randomized trial","volume":"15","author":"Cameron","year":"2010","journal-title":"Oncologist."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"N Engl J Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s10549-015-3383-6","article-title":"A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer","volume":"151","author":"Diaby","year":"2015","journal-title":"Breast Cancer Res Treat."},{"key":"B31","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s10198-011-0323-1","article-title":"Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab","volume":"13","author":"Delea","year":"2012","journal-title":"Eur J Heal Econ."},{"key":"B32","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1002\/cncr.24033","article-title":"Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer","volume":"115","author":"Le","year":"2009","journal-title":"Cancer."},{"key":"B33","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1200\/JCO.20.00147","article-title":"Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with \u22652 HER2-directed regimens: phase III NALA trial","volume":"38","author":"Saura","year":"2020","journal-title":"J Clin Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"S1288","DOI":"10.1016\/j.annonc.2021.08.2088","article-title":"LBA15 primary outcome of the phase III SYD985002\/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician's choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer","volume":"32","author":"Saura Manich","year":"2021","journal-title":"Ann Oncol."}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2022.942767\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T06:49:56Z","timestamp":1662706196000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2022.942767\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,9]]},"references-count":34,"alternative-id":["10.3389\/fpubh.2022.942767"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2022.942767","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,9]]},"article-number":"942767"}}